NCT01103180

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

SSRIs and Self-harm in Borderline Personality Disorder

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

Conditions

• Borderline Personality Disorder

Interventions

Type	Name	Description
DRUG	Escitalopram	10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)

Timeline

• Start date: 2010-09-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2010-04-14
• Last updated: 2019-06-14
• Results posted: 2019-06-14

Locations

1 site across 1 country: United States